# US 2016/0256418 A1 · Methods for administration and formulations for the treatment of regional adipose tissue

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0256418 A1
- Document ID: US20160256418A1
- Status: Published application
- Kind: A1
- Application number: 15/156,187
- Filed: 2016-05-16
- Published: 2016-09-08
- Earliest claimed: 2009-05-27
- Assignees: Neothetics, Inc.
- Applicants: Neothetics, Inc.
- Inventors: John Daniel DOBAK; Kenneth Walter LOCKE
- Web page: https://patentgrep.com/patent/US20160256418A1

## CPC

- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone}
- A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A61K 31/56: Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K 31/568: substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K 31/58: containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin (digitoxin {A61K31/7048})
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 17/00: Drugs for dermatological disorders
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are pharmaceutical formulations, methods, and systems for treating regional fat deposits and fat-related conditions and indications. Methods comprise administering a pharmaceutical formulation comprising a long-acting beta-2 adrenergic receptor agonist, for example, salmeterol, suitable for subcutaneous administration. Formulations comprise a pharmaceutical formulation that is suitable for subcutaneous injection comprising: (a) a lipophilic long-acting selective beta-2 adrenergic receptor agonist, or a salt thereof; and (b) at least one subcutaneously acceptable inactive ingredient.

## Claims

### Claim 1

An aqueous formulation comprising a formulation suitable for subcutaneous injection that comprises:
(a) an adipose tissue-reducing lipophilic long-acting selective beta-2 adrenergic receptor agonist or a salt thereof, that comprises a dose of up to about 5 micrograms of the agonist and that is suitable for subcutaneous injection; and
(b) at least one subcutaneously acceptable inactive ingredient.

### Claim 2 (depends on 1)

The formulation of claim 1 wherein the formulation is formulated as a dose of about 5 ng to about 5 micrograms.

### Claim 3 (depends on 1)

The formulation of claim 1 wherein the formulation is formulated to be administered using a single needle, multiple needles, or a needleless injection device.

### Claim 4 (depends on 1)

The formulation of claim 1 wherein the dose of the beta-2 adrenergic receptor agonist is formulated to be administered through at least 2 sub-doses.

### Claim 5 (depends on 1)

The formulation of claim 1 wherein the dose of the beta-2 adrenergic receptor agonist is formulated to be administered through at least 10 sub-doses.

### Claim 6 (depends on 1)

The formulation of claim 1 wherein the lipophilic long-acting selective beta-2 adrenergic receptor agonist is salmeterol xinafoate.

### Claim 7 (depends on 6)

The formulation of claim 6 wherein the dose of salmeterol xinafoate is formulated to be administered through at least 2 sub-doses.

### Claim 8 (depends on 7)

The formulation of claim 7 wherein a single sub-dose comprises about 20 nanograms of salmeterol xinafoate.

### Claim 9

A method of treating a patient who has excess adipose tissue or reducing adipose tissue in a patient comprising subcutaneously administering to said patient a pharmaceutical formulation that is suitable for subcutaneous injection, the formulation comprising:
(a) an adipose tissue-reducing lipophilic long-acting selective beta-2 adrenergic receptor agonist or a salt thereof, that comprises a dose of up to about 5 micrograms of the agonist; and
(b) at least one subcutaneously acceptable inactive ingredient.

### Claim 10 (depends on 9)

The method of claim 9 wherein the formulation is administered as a dose of about 5 ng to about 5 micrograms of the beta-2 adrenergic receptor agonist.

### Claim 11 (depends on 9)

The method of claim 9 wherein the dose of the beta-2 adrenergic receptor agonist is administered through at least 2 sub-doses.

### Claim 12 (depends on 9)

The method of claim 9 wherein the lipophilic long-acting selective beta-2 adrenergic receptor agonist is salmeterol xinafoate.

### Claim 13 (depends on 12)

The method of claim 12 wherein the dose of salmeterol xinafoate is administered through at least 10 sub-doses.

### Claim 14 (depends on 9)

The method of claim 9 wherein the method is a method of treating a patient who has excess adipose tissue.

### Claim 15 (depends on 9)

The method of claim 9 wherein the method is a method of reducing adipose tissue in a patient.
